Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized Bleeding Rate (ABR), All bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis may leads to higher proportion with zero bleeds compared with on‐demand therapy (low certainty).
1 finding from 1 review
Change from baseline in SF‐36v2 ‐ mental component scoreScale from: 0 to 100 (better) · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Adverse events ‐ All adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Proportion of participants with best‐corrected visual acuity of 20/40 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with cystoid macular edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs plus corticosteroids may leads to lower proportion of participants with cystoid macular edema 1 week compared with corticosteroids alone (low certainty).
1 finding from 1 review
Time to cessation of treatment · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found